---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-022588"
form_type: "8-K"
ticker: "XENE"
cik: "0001582313"
company_name: "Xenon Pharmaceuticals Inc."
filed_at: "2022-11-07T23:59:59+00:00"
generated_at: "2026-06-22T05:26:18.292216+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.45
calibrated_materiality_score: 0.45
confidence: "high"
source: SEC EDGAR
---

# Xenon Pharma appoints Andrea DiFabio as Chief Legal Officer and Corporate Secretary

## Summary
- Andrea DiFabio joined Xenon as Chief Legal Officer and Corporate Secretary effective Nov 7, 2022.
- She previously served as Chief Legal & Admin Officer at Repertoire Immune Medicines (2020-2022).
- DiFabio held CLO roles at Codiak Biosciences and Bioverativ; earlier experience at Biogen and Parexel.
- She will lead global legal strategy as Xenon advances late-stage epilepsy clinical programs.

## SEC filing metadata
- accession: 0000950170-22-022588
- form_type: 8-K
- ticker: XENE
- cik: 0001582313
- company_name: Xenon Pharmaceuticals Inc.
- filed_at: 2022-11-07T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.45
- calibrated_materiality_score: 0.45
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1582313/000095017022022588/0000950170-22-022588-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1582313/000095017022022588/xene-20221107.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-022588
- JSON: https://secwatch.observer/filing/0000950170-22-022588.json
- Plain text: https://secwatch.observer/filing/0000950170-22-022588.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.